Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

West Nile Virus Nucleic Acid Firms Will Hear Regulatory Guidance Nov. 4-5

This article was originally published in The Gray Sheet

Executive Summary

Blood banks expect to begin screening donated blood for the West Nile Virus using nucleic acid tests (NAT) by mid-2003 under an IND exemption

You may also be interested in...



West Nile Screening Is Only First Step To Broader Virus Protection – Panel

FDA hopes that efforts to develop a blood screening assay for West Nile virus will lead to technology that can be adapted to screen for other rare, endemic flaviviruses

CBER Pledges To Create Standards Boosting WNV Screening Development

FDA's Center for Biologics Evaluation & Research will establish performance criteria and standards to facilitate the development of nucleic acid tests (NAT) to screen donated blood for the West Nile virus

West Nile Screening Is Only First Step To Broader Virus Protection – Panel

FDA hopes that efforts to develop a blood screening assay for West Nile virus will lead to technology that can be adapted to screen for other rare, endemic flaviviruses

Related Content

UsernamePublicRestriction

Register

MT017423

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel